PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
Por:
O'Toole, D, Kunz, PL, Webb, SM, Goldstein, G, Khawaja, S, McDonnell, M, Boiziau, S, Gueguen, D, Houchard, A, Jr, ARO, Prebtani, A
Publicada:
1 ene 2023
Ahead of Print:
1 dic 2022
Resumen:
Introduction: Real-world data evaluating patients' injection experiences using the latest devices/formulations of the long-acting (LA) somatostatin analogs (SSAs) lanreotide Autogel/Depot (LAN; Somatuline (R)) and octreotide LA release (OCT; Sandostatin (R)) are limited. Methods: PRESTO 2 was a 2020/2021 e-survey comparing injection experience of adults with neuroendocrine tumors (NETs) or acromegaly treated with LAN prefilled syringe versus OCT syringe for > 3 months in Canada, Ireland, the UK and the USA (planned sample size, 304). Primary endpoint: the proportion of patients with injection-site pain lasting > 2 days after their most recent injection, analyzed using a multivariate logistic regression model. Secondary endpoints included interference with daily life due to injection-site pain and technical injection problems in patients with current SSA use for >= 6 months. Results: There were 304 respondents (acromegaly, n = 85; NETs, n = 219; LAN, n = 168; OCT, n = 136; 69.2% female; mean age, 59.6 years). Fewer patients had injection-site pain lasting > 2 days after the most recent injection with LAN (6.0%) than OCT (22.8%); the odds of pain lasting > 2 days were significantly lower for LAN than OCT, adjusted for disease subgroup and occurrence of injection-site reactions (odds ratio [95% confidence interval]: 0.13 [0.06-0.30]; p < 0.0001). Injection-site pain interfered with daily life "a little bit " or "quite a bit " in 37.2% and 3.8% (LAN) versus 52.5% and 7.5% (OCT) of patients, respectively. Among patients with >= 6 months' experience with current SSA (92.4% of patients), technical injection problems never occurred in 76.8% (LAN) and 42.9% (OCT) of patients. Conclusions: Compared with OCT, significantly fewer patients using LAN had injection-site pain lasting > 2 days after their most recent injection. Also, fewer LAN-treated patients experienced technical problems during injection. These findings demonstrate the importance of injection modality for overall LA SSA injection experience for patients with acromegaly or NETs.
Filiaciones:
O'Toole, D:
St Vincents Univ Hosp, Neuro Endocrine Tumours ENETS Ctr Excellence, Dublin, Ireland
Kunz, PL:
Yale Canc Ctr, Yale Sch Med, New Haven, CT USA
Webb, SM:
Univ Autonoma Barcelona, Hosp Sant Pau, Dept Med Endocrinol, IIB Sant Pau,CIBERER U747, Barcelona, Spain
Goldstein, G:
Carcinoid Canc Fdn, Mt Kisco, NY USA
Khawaja, S:
World Alliance Pituitary Org, Zeeland, Netherlands
McDonnell, M:
NET Patient Network Ireland, Dublin, Ireland
Boiziau, S:
Ipsen, Boulogne Billancourt, France
Gueguen, D:
Ipsen, Boulogne Billancourt, France
Houchard, A:
Ipsen, Boulogne Billancourt, France
Jr, ARO:
Ipsen, Cambridge, MA USA
Prebtani, A:
McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada
Bronze, Green Submitted, Green Published, All Open Access, Green
|